Subscribe to RSS
DOI: 10.1055/s-0032-1302437
Age, Male Gender, and Atrial Fibrillation Predict Lower Extremity Amputation or Revascularization in Patients with Peripheral Artery Diseases: A Population-Based Investigation
Publication History
Publication Date:
21 February 2012 (online)
![](https://www.thieme-connect.de/media/ija/201201/lookinside/thumbnails/10.1055-s-0032-1302437-1.jpg)
Abstract
By using the National Health Insurance (NHI) claim data of Taiwan, we sought to determine the predictors for nontraumatic lower extremity amputation (LEA) or peripheral revascularization procedures (PRP) in patients with peripheral artery disease (PAD). From the NHI claim data, we identified 12,206 patients with newly diagnosed PAD between 1998 and 2008, and followed them up to 2008. We explored the age, gender, and whether the patients had concomitant comorbid conditions, such as diabetes mellitus (DM), hypertension (HTN), atrial fibrillation (AF), stroke, hospitalization for coronary artery disease (CAD), myocardial infarction (MI), or heart failure (HF), and whether they were taking cilostazol at the time of recruitment. We searched for clinical parameters that might be important determinants for LEA or PRP in the study population. Of the 12,206 patients, 150 (1.2%) were found to undergo either LEA or PRP or both (LEA 81, PRP 53, both PRP and LEA 16). Old age, male gender, and history of hospitalization for CAD or MI and AF were found to be risk predictors for both procedures. Patients with DM were at lower risk for PRP (odds ratio 0.418, p = 0.001). Patients who were taking cilostazol had higher risk for LEA or PRP. HTN was not a risk predictor for LEA or PRP. From this nationwide study, we found that among PAD patients in Taiwan, age, male gender, AF, and hospitalization for CAD or MI are risk predictors for future LEA or PRP. DM is a negative predictor for PRP while both DM and HTN are not risk predictors for LEA.
Keywords
peripheral artery disease - lower extremity amputation - peripheral revascularization procedure - atrial fibrillation* These authors contributed equally to this work
-
References
- 1 Ross R. The pathogenesis of atherosclerosis—an update. N Engl J Med 1986; 314 (8) 488-500
- 2 Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344 (21) 1608-1621
- 3 Fowkes FG, Housley E, Riemersma RA , et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 1992; 135 (4) 331-340
- 4 American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003; 26 (12) 3333-3341
- 5 Kudo T, Chandra FA, Ahn SS. The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: a 10-year experience. J Vasc Surg 2005; 41 (3) 423-435 , discussion 435
- 6 Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 2006; 47 (5) 921-929
- 7 Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA 2006; 295 (5) 547-553
- 8 Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001; 24 (8) 1433-1437
- 9 Calle-Pascual AL, Redondo MJ, Ballesteros M , et al. Nontraumatic lower extremity amputations in diabetic and non-diabetic subjects in Madrid, Spain. Diabetes Metab 1997; 23 (6) 519-523
- 10 Trautner C, Haastert B, Giani G, Berger M. Amputations and diabetes: a case-control study. Diabet Med 2002; 19 (1) 35-40
- 11 Lu JF, Hsiao WC. Does universal health insurance make health care unaffordable? Lessons from Taiwan. Health Aff (Millwood) 2003; 22 (3) 77-88
- 12 Chiang TL. Taiwan's 1995 health care reform. Health Policy 1997; 39 (3) 225-239
- 13 Tseng CH. Mortality and causes of death in a national sample of diabetic patients in Taiwan. Diabetes Care 2004; 27 (7) 1605-1609
- 14 Chen HF, Ho CA, Li CY. Age and sex may significantly interact with diabetes on the risks of lower-extremity amputation and peripheral revascularization procedures: evidence from a cohort of a half-million diabetic patients. Diabetes Care 2006; 29 (11) 2409-2414
- 15 Garcia LA. Epidemiology and pathophysiology of lower extremity peripheral arterial disease. J Endovasc Ther 2006; 13 (Suppl 2) II3-II9
- 16 Guzman RJ, Brinkley DM, Schumacher PM, Donahue RM, Beavers H, Qin X. Tibial artery calcification as a marker of amputation risk in patients with peripheral arterial disease. J Am Coll Cardiol 2008; 51 (20) 1967-1974
- 17 Ryder KM, Benjamin EJ. Epidemiology and significance of atrial fibrillation. Am J Cardiol 1999; 84 (9A) 131R-138R
- 18 Lee TT, Cheng SH, Chen CC, Lai MS. A pay-for-performance program for diabetes care in Taiwan: a preliminary assessment. Am J Manag Care 2010; 16 (1) 65-69
- 19 Creager MA. Medical management of peripheral arterial disease. Cardiol Rev 2001; 9 (4) 238-245
- 20 Igawa T, Tani T, Chijiwa T , et al. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res 1990; 57 (4) 617-623
- 21. Kohda N, Tani T, Nakayama S , et al. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res 1999; 96 (4) 261-268
- 22 Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2008; (1) CD003748
- 23 Regensteiner JG, Ware Jr JE, McCarthy WJ , et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002; 50 (12) 1939-1946
- 24 Tsuchikane E, Fukuhara A, Kobayashi T , et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999; 100 (1) 21-26
- 25 Douglas Jr JS, Holmes Jr DR, Kereiakes DJ , et al; Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112 (18) 2826-2832
- 26 Iida O, Nanto S, Uematsu M , et al. Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery. Circ J 2005; 69 (10) 1256-1259
- 27 Assaf AR, Lapane KL, McKenney JL, Carleton RA. Possible influence of the prospective payment system on the assignment of discharge diagnoses for coronary heart disease. N Engl J Med 1993; 329 (13) 931-935